CASI - CASI Pharmaceuticals, Inc.
| Previous Close | 3.1500 |
| Open | 3.1400 |
| Bid | 3.1300 x 1300 |
| Ask | 3.1400 x 800 |
| Day's Range | 3.1100 - 3.1700 |
| 52 Week Range | 2.8300 - 4.5800 |
| Volume | 23,158 |
| Avg. Volume | 123,064 |
| Market Cap | 302M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops...
- Zacks
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
- GuruFocus.com
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $64,000 of Shares
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share. Continue reading...
- Simply Wall St.
What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful...
- Zacks Small Cap Research
CASI: CASI launches Evomela - first commercial product
On August 12,2019, CASI Pharmaceuticals (CASI) announced the commercial launch of Evomela, the only approved and commercially available form of melphalan available in China. This is the Company’s first commercialized product and we are encouraged to see that volatile trade tensions between the US and China do not appear to be hampering CASI’s progress towards establishing its footprint as a leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. Sharp price decreases often go hand-in-hand with inclusion on various “approved” drug lists in China, and we believe that CASI will opt for the lower-price/higher market share route in part to suppress potential competition.
- GuruFocus.com
Casi Pharmaceuticals Inc (CASI) CEO Wei-wu He Bought $507,200 of Shares
CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share. Continue reading...
- Zacks
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
- Zacks Small Cap Research
CASI: Making headway towards commercialization
CASI Pharmaceuticals, Inc. (CASI) is establishing its footprint as a leading provider of high-quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. CASI’s management sees China as a sustainable opportunity and is investing with this in mind. With a robust, diverse pipeline, commitment to investing in new opportunities and ample cash, we believe that CASI Pharmaceuticals will firmly establish itself over the next several years as a leading player in China.
- Zacks Small Cap Research
CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond
We initiated coverage of CASI Pharmaceuticals, Inc. (CASI) with a target price of $8.17. CASI is establishing its footprint as a leading provider of high-quality proprietary, licensed and ANDA pharmaceuticals to the rapidly evolving Chinese market. CASI’s management sees China as a sustainable opportunity and is investing with this in mind.
- Zacks
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
Ligand (LGND) first-quarter earnings and sales decrease year over year.
- Simply Wall St.
When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. The company’s loss has recently broadened since it announcedRead More...
- Simply Wall St.
Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...
